Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Background:
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: November 2019: The following drug classes/subclass and newly approved agents will be reviewed:
Antidepressants and Non-Opioid Pain Syndrome Agents, SUB CLASS: Serotonin-Norepinephrine Reuptake Inhibitors - Drizalma
Pulmonary-2 Agents, SUB CLASS: Chronic Obstructive Pulmonary Disease - Duaklir Pressair
Binders Chelators Antidotes Overdose, SUB CLASS: NA - Gvoke
Anticonvulsants-Antimania Agents, SUB CLASS: NA - Nayzilam
Parkinsons Agents, SUB CLASS: NA - Nourianz
Diabetes Non-Insulin, SUB CLASS: Glucagon-Like Peptide-1 (GLP) Receptor Agonists Oral - Rybelsus
Diabetes Non-Insulin, SUB CLASS: Glucagon-Like Peptide-1 (GLP) Receptor Agonists - Rybelsus
Migraine Agents, SUB CLASS: Triptans - Tosymra
Sleep Disorders, SUB CLASS: Wakefulness Promoting Agents - Wakix
RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein.
There is no pre-proposal teleconference. Rather, questions shall be submitted via e-mail to the Request for Quote (RFQ) Point of Contact stated in Part 2.3, no later than the date stated in Part 2.4. Also, responses to Part 3.4 is required.
POCs: Part 2.3 of the RFQ.
For additional information, search DoD Pharmacy and Therapeutics (P&T) Committee at http://www.health.mil/POD
Alexia Ray, Contract Analyst, CTR, Phone 210-536-6020, Email alexia.m.ray.ctr@mail.mil - Yvette H. Dluhos, Contract Specialist, Phone 210-536-6048, Email yvette.h.dluhos.civ@mail.mil
